NOLA Therapeutics develops cancer drug treatments using nanotechnology and antibody therapy.
Michael Strong, MD/PhD candidate
James Morgan Dixon, MS Biomedical Engineering, MBA candidate
Gary Mouradian, PhD, Postdoctoral fellow
Juan Carlos Vera, MD, MS candidate in Clinical Research
Yingchun Ba, MBA candidate
Arpit Bhopalkar, MBA candidate
Ryan Hildebrand, MBA candidate
Christine Soliva, MBA
Glioblastoma multiforme (GBM), although rare compared to other cancers, is the most common malignant brain tumor. Temozolomide is the standard of care for treatment of GBM in conjunction with surgery and radiation. Unfortunately, 60% of GBM patients treated with Temozolomide experience tumor regrowth within one year of treatment. Since Temozolomide is a non-specific chemotherapeutic agent, there are side effects including immunosuppression and seizures.
Scientists at the NIH discovered a key protein called Anti-Tumor Necrosis Factor Induced Apoptosis (ATIA) that protects and promotes the spread of GBM cells. Our product, N1, selectively targets and inhibits ATIA. The drug is a biologically enhanced antibody-targeted radiosensitizing chemotherapeutic that links an RNA-based inhibitor, surrounded by a biodegradable nanoparticle polymer, to a monoclonal antibody specific for ATIA.
The GBM treatment market is forecasted to grow from $301 M in 2013 to $623 M in 2020 with a CAGR of 10.9%. There are 15,000 GBM new cases diagnosed annually in the US.
We will validate the technology through pre-clinical and Phase 1 clinical trials, and seek orphan drug designation. To attract strategic partners, we will publish in peer-reviewed journals and attend oncology conferences.
Compared to other anti-cancer agents that kill both healthy and GBM cells, N1 specifically targets GBM, resulting in fewer side effects, shorter treatment time, and fewer recurrences.
In addition to the US, the company will pursue patents in UK, France, Germany, Italy, and
Spain, where the incidence of GBM is high.
We need $3M to fund the 5-year pre-clinical and Phase 1 clinical trials that will produce validation data, making the company an attractive acquisition target for pharmaceutical companies.